This is an open-label, single-center pilot study to investigate the pharmacodynamics, pharmacokinetics (PK), safety, and activity of pembrolizumab administered intra-lymphatically using the DoseConnect in participants with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
All participants will receive the study intervention, pembrolizumab administered intralymphatically using the Sofusa DoseConnect device.
